Phase 2 Trial of Neovacs’ Lupus Interferon Immunotherapy Receives Another Review Board Sign-off
Neovacs’ Phase 2b clinical trial of an interferon immunotherapy for lupus is going according to plan, the company announced after an independent review board declined to recommend modifications to the study. The trial is evaluating interferon (IFN)-alpha kinoid immunotherapy as a treatment for systemic lupus erythematosus. One hundred seventy-eight patients with moderate…